|
|
Office Locations:
|
304, 3rd Floor Tower A Peninsula Business Park
Ganpatrao Kadam Marg Lower Parel
Mumbai, 400 013
India
Phone: 91-22-6655-4200
| |
|
|
|
|
Business Services
Consumer Products & Services
Education & Training
Financial Services
Information Technology
Life Sciences & Healthcare
Real Estate & Construction
Software & Internet
|
|
|
Founded in 2008, Eight Roads (along with F-Prime Capital - see profile) was born out of Fidelity Investment's first principal investment business, Fidelity Ventures. The firm is active in Ventures, Principal Investments and Real Estate, and invests across the U.S., Asia, and Europe. Over the past 20 years, Eight Roads has supported, championed and backed over 300 companies. Since 2008, the firm has invested almost $11 billion globally into growing companies in technology and healthcare. The firm invests in early mid and late stage companies, with an interest in information technology, communications, systems, software and services, financial services and finTech, consumer and enterprise technology, and consumer sector. Eight Roads typically invests between $1.29 million and $12.95 million in companies with enterprise values between $16.25 million and $325.02 million. They prefer to be the lead investor and can co-invest with other tier one venture capital firms in its portfolio companies.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
Aishwarya Arunkumar | |
| |
VP | |
Daniel Auerbach | |
| |
Senior Managing Partner | |
David Milstein | |
| |
Managing Partner | |
Jarlon Tsang | |
| |
Managing Partner | |
Ju Zhang | |
| |
Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
01/22/2025
|
Eleos Health
|
MA
|
$60,000,000
|
Series C
|
10/22/2024
|
AvenCell Therapeutics
|
MA
|
$112,000,000
|
Series B
|
10/01/2024
|
Eon
|
NY
|
$127,000,000
|
Seed, Series A, and Series B
|
07/09/2024
|
Canoe Intelligence
|
NY
|
$36,000,000
|
Series C
|
06/27/2024
|
Odaseva
|
CA
|
$54,000,000
|
Series C
|
06/27/2024
|
Feon Energy
|
MA
|
$6,100,000
|
Seed
|
03/28/2024
|
Pelago
|
NY
|
$58,000,000
|
Series C
|
03/19/2024
|
Engrail Therapeutics
|
CA
|
$157,000,000
|
Series B
|
|
|
|
|
|